Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. Jentashapir Journal of Cellular and Molecular Biology
  4. Articles

  5. Cytotoxic Effects of Flubendazole in Human Lung Cancer Cell Line A549
  6. Scopus by Title (Ref)

Jentashapir Journal of Cellular and Molecular Biology

Official Journal of Ahvaz Jundishapur University of Medical Sciences

homeHome
play_circleCurrent IssuelistAll Issuesformat_indent_increaseIn PresssearchSearchcheck_circleAccepted Manuscripts
settingsInstructions
groupsEditors & BoardsinfoJournal InformationemailSupportshareIndexing and Listing Sourcesassignment_indReviewer and AE Registration Formshow_chartJournal MetricsbalancePublication Ethics and Malpractice StatementphoneContact Uszoom_inOpen Peer Review (OPR)
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. A Systematic Review of the Impact of Benzimidazole-based Anthelmintics on Lung Cancer in Animal Models

- Garg A. , et al.

2. Revisiting Flubendazole Through Nanocrystal Technology: Statistical Design, Characterization and Its Potential Inhibitory Effect on Xenografted Lung Tumor Progression in Mice

- de Souza Gonçalves D. , et al.

HomeInstructions

Articles

  • Current Issue
  • All Issues
  • In Press
  • Search
  • Accepted Manuscripts

About Journal

  • Editors & Boards
  • Journal Information
  • Support
  • Indexing and Listing Sources
  • Reviewer and AE Registration Form
  • Journal Metrics
  • Publication Ethics and Malpractice Statement
  • Contact Us
  • Open Peer Review (OPR)
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.